Compounded
Semaglutide
Any prescribed dose up to 2.5 mg/week
Prescription & clinician review included
Shipping included
$948 due today
Back to All Reviews
Investigation Report
Empower Pharmacy Semaglutide Review
Empower Pharma, Empower Clinic Services LLC, empowerpharmacy.com
Also spelled as Empower Pharma, Empower Clinic Services LLC, empowerpharmacy.com — Same brand, same great service!
Our investigation of Compounded Semaglutide from Empower Pharmacy
Caution Advised
Multiple red flags identified
3.5/10
Caution AdvisedRank#115 of 226
Visit Empower PharmacyPrescription treatment requires clinician review
Caution Advised
Not sold directly to patients—pricing is set by the prescribing telehealth provider or clinic
100+
Hours Researched
6
Verified Pros
8
Issues Found
3.5
Final Score
These are Med Consumer Watch products, not products from Empower Pharmacy, the brand being reviewed on this page.
Med Consumer Watch GLP-1 plans
GLP-1 weight loss.
A brand on your side.
Med Consumer Watch exists to help consumers make informed choices. Our brand brings that mission to GLP-1 care: clear plan prices, clinician review and support included, so you can compare your options and get started with confidence.
Why choose Med Consumer Watch?
Know your full price
Medication, clinician review and shipping are included. See your total before you buy.
Same price at every included dose
Your plan price stays the same across its included prescribed doses. Choose 1, 3, 6 or 12 months.
Support beyond your prescription
Ongoing doctor messaging, health coaching and patient community access are included with your plan.
Choose your medication and the plan length that works for you.
Buy semaglutide
Compounded
Tirzepatide
Any prescribed dose up to 15 mg/week
Prescription & clinician review included
Shipping included
$1,548 due today
Treatment requires a prescription and clinician approval. If treatment is declined, your payment is refunded. Compounded medications are not FDA-approved.
Investigation Overview
Empower Pharmacy is not a telehealth provider and you cannot buy from it directly. It is a compounding pharmacy—and it matters here because it is one of the largest suppliers behind the compounded GLP-1 telehealth market. If a provider will not tell you which pharmacy fills your prescription, this is one of the names that could be behind it.
Our research (August 8, 2026) found a substantial operation with a federal enforcement record that a patient deserves to know about.
What It Is
Empower describes itself as "the nation's premier 503A compounding pharmacy and 503B outsourcing facility"—it operates as both, which is unusual. As we set out in our guide to brand-name versus compounded GLP-1s, 503A is traditional patient-specific compounding regulated by state boards, while 503B outsourcing facilities are FDA-registered, subject to federal cGMP requirements, and inspected by the FDA. Its GLP-1 products are semaglutide with cyanocobalamin (vitamin B12) and tirzepatide with niacinamide (vitamin B3), plus a tirzepatide orally dissolving tablet. Note that these are combination preparations, not plain semaglutide or tirzepatide. You cannot order from Empower. Its own site states: "All of our medications require a prescription from a licensed prescriber." It supplies patients, practitioners and pharmacies through prescribers.The FDA Enforcement Record
This is why the rating is what it is, and all of it is public record. Warning letter 613792, dated October 15, 2021, issued to Empower Clinic Services LLC dba Empower Pharmacy. Warning letter 700962, dated April 2, 2025, issued to Empower Clinic Services LLC dba Empower Pharma—one of two letters issued that month (the other numbered 700964), following FDA inspections of two Houston facilities between August and October 2024. There was also a warning letter in 2017, and Form 483 inspection observations in 2020 and 2024.What the 2025 Letters Cited
The findings concern sterile injectable manufacturing, which is the most consequential area a compounder can fail in:- Insanitary conditions in the production of drugs intended to be sterile—the FDA noted products were prepared, packed or held in conditions that could have led to contamination
- Inadequate environmental monitoring in ISO 5 areas
- Media fills not performed under worst-case conditions
- Failure to sterilise critical equipment, including stopper sorting bowls
- Inadequate investigation of microbial excursions
- Labelling omissions that disqualified 503B exemptions
The Semaglutide-Specific Finding
FDA Form 483 observations from May 2024 documented fill weight discrepancies in semaglutide vials, alongside inadequate quality control sampling procedures and deficiencies in aseptic processing areas. Fill weight discrepancy in an injectable means the amount of drug in the vial may not match what the label says. For a medication titrated by dose, that is a direct patient-facing problem—it affects how much you are actually injecting.Litigation
Eli Lilly filed two lawsuits against Empower in 2025—April 2025 in New Jersey and July 2025 in Texas—alleging unlawful manufacturing and misleading marketing of tirzepatide products. Lawsuits are allegations, not findings, and Lilly is an interested commercial party. We note them for completeness rather than as evidence of wrongdoing.Our Investigation Summary
Our research (August 8, 2026) verified Empower Pharmacy's federal enforcement record from primary FDA sources. The company operates as both a 503A compounding pharmacy and a 503B outsourcing facility from Houston, compounding semaglutide with cyanocobalamin and tirzepatide with niacinamide, and does not sell directly to patients—all medications require a prescriber. FDA warning letters were issued in 2017, on October 15, 2021 (613792), and on April 2, 2025 (700962, one of two that month alongside 700964), the last following inspections of two Houston facilities between August and October 2024. The 2025 letters cited insanitary conditions in sterile drug production, inadequate ISO 5 environmental monitoring, media fills not performed under worst-case conditions, failure to sterilise critical equipment including stopper sorting bowls, inadequate investigation of microbial excursions, and labelling omissions disqualifying 503B exemptions. One facility released a pyridoxine HCl injection batch despite microbial recovery in the aseptic area, later recalled. Form 483 observations from May 2024 documented fill weight discrepancies in semaglutide vials. The FDA stated that repeated lapses demonstrate inadequate executive management oversight. Eli Lilly filed suits in April and July 2025 alleging unlawful tirzepatide manufacturing. This is a supplier, not a provider—the practical action for a patient is to ask which pharmacy fills their prescription.
How Empower Pharmacy Works
1
Empower does not sell to patients directly—all medications require a prescription from a licensed prescriber
2
A telehealth provider or clinician sends a prescription to Empower as either a 503A patient-specific compound or a 503B bulk order
3
Empower compounds semaglutide with cyanocobalamin, or tirzepatide with niacinamide, and ships most orders within one to three business days
4
The medication may reach you branded by the telehealth provider rather than by Empower
5
To find out whether your medication comes from here, ask your provider directly: which pharmacy fills my prescription, and is it 503A or 503B?
6
If the answer is Empower, ask for the certificate of analysis for your specific batch
What We Found
What's Good
- Operates as both a 503A compounding pharmacy and an FDA-registered 503B outsourcing facility, which subjects it to federal cGMP requirements and FDA inspection
- A large, established operation with substantial capacity supplying prescribers and clinics nationally
- Ships most orders within one to three business days
- Advertises extended beyond-use dating across many products
- Requires a prescription from a licensed prescriber for all medications—no direct-to-consumer sales without a prescriber
- Being FDA-registered means its inspection record is public and checkable, which is more than can be said for pharmacies that telehealth providers decline to name
Watch Out For
- Three FDA warning letters—2017, October 2021 (613792) and April 2025 (700962)—plus Form 483 observations in 2020 and 2024
- The April 2025 letters cited insanitary conditions in the production of drugs intended to be sterile
- Cited for inadequate ISO 5 environmental monitoring, media fills not run under worst-case conditions, and failure to sterilise critical equipment including stopper sorting bowls
- A pyridoxine HCl injection batch was released despite microbial recovery in the aseptic area, and later recalled
- May 2024 Form 483 documented fill weight discrepancies in semaglutide vials—a dose-accuracy issue
- The FDA stated that repeated lapses demonstrate inadequate executive management oversight
- GLP-1 products are combination preparations (with B12 or niacinamide) rather than plain semaglutide or tirzepatide
- Eli Lilly filed lawsuits in April and July 2025 alleging unlawful tirzepatide manufacturing
Pricing Breakdown
Starting Price
Not applicable—Empower does not sell directly to patients
Medication Cost
Set by the prescribing telehealth provider or clinic, not by Empower. The compounded products are semaglutide/cyanocobalamin and tirzepatide/niacinamide injections
Subscription Fees
None—this is a pharmacy supplying prescribers, not a consumer subscription service
Hidden Fees
Not applicable. The relevant cost question is what your telehealth provider charges, which is covered in our individual provider reviews
Safety & Medical Oversight
This entry exists because patients are entitled to know who makes their medication. Empower is one of the larger compounders supplying the telehealth GLP-1 market, and its FDA record is a matter of public concern. The FDA has issued warning letters in 2017, October 2021 (613792) and April 2025 (700962, with a second letter 700964), the most recent following inspections of two Houston facilities between August and October 2024. Those letters cited insanitary conditions in the production of drugs intended to be sterile, inadequate ISO 5 environmental monitoring, media fills not conducted under worst-case conditions, failure to sterilise critical equipment including stopper sorting bowls, and inadequate investigation of microbial excursions. One facility released a pyridoxine HCl injection batch despite microbial recovery in the aseptic area; the lot was recalled. FDA Form 483 observations from May 2024 documented fill weight discrepancies in semaglutide vials—meaning the quantity of drug in a vial may not match the label, which matters directly for a dose-titrated medication. The FDA concluded that repeated lapses demonstrate inadequate executive management oversight. Note also that Empower's GLP-1 products are combination preparations—semaglutide with cyanocobalamin, tirzepatide with niacinamide—not plain semaglutide or tirzepatide, and those additives were not part of the clinical trials that established these drugs work. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or manufacturing quality before reaching patients.
Customer Support
Empower's customer relationship is with prescribers and clinics rather than patients—it states that all medications require a prescription from a licensed prescriber, and it ships most orders within one to three business days. It advertises extended beyond-use dating across many products. If you are a patient with a question about a medication compounded here, your route is through the prescriber who ordered it, not directly to the pharmacy. That indirect relationship is itself worth understanding: if something goes wrong with a compounded medication, the entity that made it is one step removed from you.
Key Features
503A Compounding Pharmacy
503B Outsourcing Facility (FDA-Registered)
Semaglutide / Cyanocobalamin Injection
Tirzepatide / Niacinamide Injection
Tirzepatide Orally Dissolving Tablet
Prescriber-Only—No Direct Patient Sales
1–3 Business Day Shipping
Houston, Texas
Best For
Nobody buys from Empower directly. This entry exists so patients can recognise the name and ask their provider the question that matters: which pharmacy fills my prescription?
Customer Reviews & Complaints
Empower is a pharmacy supplying prescribers rather than a consumer brand, so the meaningful record is regulatory rather than customer reviews. We reviewed public FDA enforcement records as of August 8, 2026.
FDA warning letters: 2017; 613792 on October 15, 2021; and 700962 on April 2, 2025, one of two issued that month alongside 700964. Form 483 inspection observations were recorded in 2020 and 2024.
The April 2025 findings, following inspections of two Houston facilities between August and October 2024, concerned sterile injectable production: insanitary conditions, inadequate environmental monitoring in ISO 5 areas, media fills not performed under worst-case conditions, failure to sterilise critical equipment such as stopper sorting bowls, inadequate investigation of microbial excursions, and labelling omissions that disqualified 503B exemptions.
A specific incident: one facility released a pyridoxine HCl injection batch despite microbial recovery in the aseptic area. The lot was later recalled.
The semaglutide-specific finding: FDA Form 483 observations from May 2024 documented fill weight discrepancies in semaglutide vials, plus inadequate quality control sampling and aseptic processing deficiencies. For a dose-titrated injectable, a fill weight discrepancy means the amount in the vial may not match the label.
The FDA's own conclusion: repeated lapses "demonstrate that executive management oversight and control over the manufacture of drugs is inadequate." That is a statement about systems and leadership rather than a single batch.
Litigation: Eli Lilly filed suits in April 2025 (New Jersey) and July 2025 (Texas) alleging unlawful manufacturing and misleading marketing of tirzepatide. These are allegations by a commercial competitor, not findings, and we report them as such.
Is Empower Pharmacy Legit?
"Is Empower Pharmacy safe?" is a question patients usually ask after discovering their telehealth provider used it. Our assessment as of August 8, 2026.
Official Verification: Empower is a real, licensed, substantial operation—a 503A compounding pharmacy and an FDA-registered 503B outsourcing facility based in Houston. It is not a fake pharmacy and it is not operating in the shadows. Being FDA-registered is precisely why its inspection record is public and why we can write this entry at all.
What the record shows: three FDA warning letters across 2017, 2021 and 2025, with Form 483 observations in between. The most recent citations concern insanitary conditions in sterile drug production—the most serious category of finding for a facility making injectables—alongside inadequate environmental monitoring, unsterilised critical equipment, and a released batch with microbial recovery that was subsequently recalled. The FDA's assessment was that executive management oversight is inadequate.
What that does and does not mean for you: it does not mean every vial is contaminated, and it does not mean patients have been harmed. Warning letters describe systemic deficiencies found during inspection, and companies do remediate. But sterile injectable manufacturing is the one area where process failures translate most directly into patient risk, and a fill weight discrepancy in semaglutide vials is a dose-accuracy problem with an obvious clinical consequence.
Red Flags Check:
- ✓ Real, licensed 503A pharmacy and FDA-registered 503B facility
- ✓ Requires a prescription from a licensed prescriber for all medications
- ✓ Public, checkable FDA inspection record
- ⚠ Three FDA warning letters: 2017, October 2021, April 2025
- ⚠ Insanitary conditions cited in sterile drug production, April 2025
- ⚠ Fill weight discrepancies documented in semaglutide vials, May 2024
- ⚠ Batch released despite microbial recovery, subsequently recalled
- ⚠ FDA: repeated lapses demonstrate inadequate executive management oversight
- ⚠ GLP-1 products are combination preparations with additives not present in the trialled drugs
Assessment: This is not a scam and not an unlicensed operation. It is a large, regulated compounder with a repeated pattern of serious sterile-manufacturing findings, documented by its own regulator across three warning letters and eight years.
The Bottom Line: The practical action is not to avoid a name—it is to ask your telehealth provider which pharmacy fills your prescription, and whether it is 503A or 503B. Then look that pharmacy up in the FDA's public inspection and warning letter records, which takes about two minutes. A provider that will not name its pharmacy is preventing you from doing exactly this check. As always, discuss any concern about a medication you are taking with your prescribing clinician rather than stopping treatment on your own.
Our Verdict: Caution Advised
Empower Pharmacy has a 3.5/10 site score. We've identified some concerns that potential customers should be aware of. We recommend reviewing our top picks before proceeding.
Visit Empower PharmacyEmpower Pharmacy
Caution Advised
3.5/10
Not sold directly to patients—pricing is set by the prescribing telehealth provider or clinic
Prescription treatment requires clinician review
Investigation Summary
Overall Rank#115 of 226
Rating3.5/10
StatusCaution Advised
PricingNot sold directly to patients—pricing is set by the prescribing telehealth provider or clinic
Share Your Experience
Help others by sharing your experience with Empower Pharmacy
Want to compare options?
View All 226 ProvidersUser Reviews
Rating Summary
No ratings yet
Rate your experience
Click a star to rate and add a review
Questions & Discussions
226 Providers Reviewed
Explore Other Reviews
Compare with other GLP-1 weight loss providers we've investigated
Our Top Picks
Promotional placement: CoreAge Rx is featured #1 and SuperHealthy Rx #2. Placements and site scores are not independent clinical ratings or patient review averages. We may earn compensation from referral links. How our rankings work.
#1 RecommendedExcellent
#2 RecommendedExcellent
#3 RecommendedGreat
Mochi Health
8.8
Affordable GLP-1 Access Starting at $99/Month with No Long-Term Commitment
More Provider Reviews
CoreAge Rx
9.9
SuperHealthy Rx
9.7
Mochi Health
8.8
Remedy Meds
8.3
Caution Advised
Ready to Get Started with Empower Pharmacy?
Review our findings above and make an informed decision about Empower Pharmacy.
Enter to Win a $1,788 CoreAge Rx Gift Card
Enter for a chance to use it toward eligible CoreAge Rx products and services.
The gift card may be applied toward eligible CoreAge Rx products and services. Prescription products additionally require completing the intake process and evaluation by a licensed healthcare provider, who alone decides eligibility and treatment. Winning does not guarantee that you will qualify for a GLP-1 medication or any other prescription treatment.